The insulin crisis America has created is not a distant policy debate. It’s playing out in pharmacy lines, in skipped doses, in people driving across the border to Canada just to afford a medicine discovered over a hundred years ago. The headlines have come and gone, the political speeches have been made, and a few laws have passed – and yet millions of Americans are still deciding each month whether they can actually afford to stay alive.
Insulin is not a new drug, not a cutting-edge treatment, not some experimental therapy with a brief supply chain. It’s a hormone the human body either produces or doesn’t, and without it, people with Type 1 diabetes die. The human cost of what happened to its price over the past three decades is hard to overstate – the deaths are documented, the coverage gaps are real, and the story isn’t close to finished. Here are ten facts that every American should understand about the insulin crisis.
1. Around 8.4 Million Americans Depend on Insulin to Survive
About 8.4 million Americans rely on insulin, and for those with Type 1 diabetes, it is not optional. The pancreas simply does not produce it. People with Type 1 cannot produce enough insulin on their own, while those with Type 2 cannot effectively use what their bodies do make. Missing a dose isn’t a minor inconvenience – without insulin in the bloodstream, the body begins breaking down fat for fuel at a dangerous rate, producing toxic acids that can spiral into a coma within hours.
According to the CDC’s 2026 National Diabetes Statistics Report, 40.1 million Americans have diabetes in some form. The fraction who require insulin to function is only part of that population, but it’s the part for whom a coverage gap or a price spike carries consequences measured in days, not years.
2. The Price of Insulin Rose Over 1,000% in Two Decades
The number that stops people cold: a vial of Humalog (insulin lispro) was $21 in 1999 and cost $332 in 2019 – a price increase of more than 1,000%. That increase had nothing to do with the cost of making insulin going up. It had everything to do with the structure of the American drug pricing system, and the near-total lack of competition at the top.
Insulin is produced by three major manufacturers in the U.S.: Eli Lilly, Novo Nordisk, and Sanofi. The pricing chain runs through pharmacy benefit managers – third-party organizations that negotiate drug prices on behalf of insurers, collect rebates from manufacturers based on a percentage of list price, and leave patients often paying the full undiscounted amount. Those rebate incentives, stacked on top of absent competition, let prices climb essentially unchecked for the better part of two decades.
3. It Costs as Little as $2 to $4 to Manufacture a Vial
This is the number that tends to make people set down whatever they’re holding. It costs manufacturers an estimated $2 to $4 to produce a vial of insulin, according to Yale School of Medicine endocrinologist Kasia Lipska, whose research on insulin pricing has been referenced in Congressional hearings. The same vial sold for hundreds of dollars. That gap between production cost and retail price isn’t explained by research and development costs either – even the most commonly used analog insulins have been on the market for over two decades.
When physician Frederick Banting co-discovered insulin in 1923, he and his co-inventors sold the patent to the University of Toronto for $1, determined that a life-saving drug shouldn’t enrich them personally. Three companies now control more than 90% of the supply, none of which faced meaningful price competition for decades – a structure that let prices rise far beyond what any production cost could justify.
4. American Patients Pay Up to Ten Times More Than Patients in Other Countries
According to a RAND Corporation report, the gross price of insulin in the United States is more than nine times higher than in 33 high-income comparison nations. Even after accounting for the rebates and discounts manufacturers provide, the price per insulin unit remained 2.3 times higher in the United States than in comparable countries.
That gap isn’t a rounding error or a quirk of exchange rates. It reflects a fundamental difference in how the U.S. allows the pharmaceutical market to operate compared to virtually every other wealthy country. People drove across the border to buy insulin in Canada – not as a curiosity, but as a genuine survival strategy.
5. Insulin Rationing Became a Nationwide Crisis – and It’s Still Happening
When people can’t afford their insulin, they don’t simply go without. They ration it – stretching doses further than they should, skipping injections, using expired supplies. A 2025 Yale School of Medicine study published in the Journal of General Internal Medicine found that one in four patients at the Yale Diabetes Center rationed insulin due to cost in 2024, a rate unchanged from 2017 despite years of policy changes. When researchers added rationing caused by insurance delays and pharmacy shortages, 37% of patients reported having rationed over the previous year.
The Inflation Reduction Act capped out-of-pocket insulin costs for Medicare beneficiaries, but the majority of adults who reported rationing were too young to qualify. A 2023 study found that one in five U.S. adults under the age of 65 using insulin reported rationing it because of cost. The populations most likely to ration include people with Type 1 diabetes, Black Americans, and middle-income earners who earn too much for assistance programs but not enough to absorb the full cost.
6. Rationing Insulin Can Kill – and It Has
Rationing insulin isn’t a financial hardship people bounce back from. It can trigger diabetic ketoacidosis (DKA) – a condition in which the body, starved of insulin, begins producing acidic compounds called ketones faster than the blood can buffer them. Left untreated, DKA can be fatal within hours.
The Right Care Alliance, a coalition of patients and healthcare providers, has documented at least 14 deaths of Americans who died while rationing insulin since 2017 – and the true number is almost certainly higher, since not every death from diabetes complications gets investigated for cost-related causes. The deaths fell disproportionately on young adults who had just aged out of their parents’ health insurance and couldn’t cover the uninsured cost of insulin. Their stories forced Congressional hearings and put pharmaceutical executives in front of lawmakers who, for once, had real names to go with the numbers.
7. The Three Big Manufacturers Control More Than 90% of the Market
The three major manufacturers – Sanofi, Novo Nordisk, and Eli Lilly – make up more than 90% of the insulin market. Three companies holding nearly the entire supply with no meaningful price competition for decades is why prices could rise so far with so little resistance. When going without is your only real alternative, you have no bargaining power.
Their pricing behavior also tracked each other closely over the years. When one raised prices, the others typically followed within months – a pattern economists call “shadow pricing.” In March 2023, all three announced insulin cost cuts in response to growing public pressure. Eli Lilly reduced costs by 70% and capped out-of-pocket expenses at $35 for individuals without private insurance; Novo Nordisk followed with cuts of up to 75%; and Sanofi cut prices on its most-prescribed brand by 78%, capping vial costs at $35 for people with private insurance.
8. The Inflation Reduction Act Capped Insulin at $35 for Medicare – But Left Millions Without Coverage
Effective January 1, 2023, out-of-pocket costs for insulin were capped at $35 per monthly prescription for Medicare Part D enrollees under the Inflation Reduction Act. The $35 copay cap became available across all 6,000 Part D plans in 2024. For seniors who had previously been spending far more, that change mattered enormously.
But the cap only applies to Medicare. For people with private insurance or no insurance at all, access to the $35 cap isn’t automatic – it depends on whether their insurer covers them or whether a manufacturer’s voluntary savings program applies. Federal price caps on insulin cover government programs like Medicare and Medicaid. For uninsured patients, no such protection exists. They pay whatever they’re charged.
9. Uninsured Patients Paid Nearly Double the National Average
Nationally, the average out-of-pocket cost was $58 per insulin fill for a 30-day supply, according to U.S. Department of Health and Human Services data. For people who were completely uninsured, the average cost per fill was $123. For someone managing Type 1 diabetes who needs multiple vials per month, that math compounds fast.
In 2019, uninsured patients paid nearly double the national average for insulin. In 2021, 29% of those without health insurance reported rationing their insulin. Patients without coverage pay more than quadruple what insured patients pay for the same medication – meaning the most financially vulnerable carry the highest cost. The crisis doesn’t spread evenly. It concentrates at the bottom.
10. Insulin Prices Have Fallen – But the Story Isn’t Over
There has been genuine progress. The average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19 in mid-2024 – the lowest average recorded in a decade. This reflects a combination of legislative action, including Medicare caps introduced by the Inflation Reduction Act, and voluntary price cuts by all three major manufacturers.
But list price progress doesn’t automatically reach every patient. Manufacturer savings programs are voluntary, and nothing legally prevents companies from withdrawing them without notice. For the roughly 37% of insulin users still rationing as of 2024, whether the $35 cap or a manufacturer discount actually applies depends on a tangle of insurance status, plan type, and program eligibility that can take hours to sort out – time and energy that sick people often don’t have.
Read More: States Where Seniors Live the Longest
What This Means Right Now
The insulin crisis in America is not a solved problem with a few loose ends. It’s a partially addressed crisis with structural issues that haven’t changed. Three companies still control over 90% of the supply. Federal price caps still cover Medicare but don’t reach the millions of working-age adults with commercial insurance or no coverage at all. Voluntary manufacturer programs can disappear with no warning. And 37% of people who need insulin every day are still stretching doses they can’t afford to stretch.
What has improved is real: the $35 Medicare cap, the manufacturer pricecuts, and the broader drug negotiation process under the Inflation Reduction Act have all reduced costs for specific populations. Those are not nothing. But a system where someone has to know the right coupon code, be enrolled in the right plan, and live in the right state just to afford a drug that costs $3 to make is not a fixed system. It’s a patched one. The patch covers some people. For the people it doesn’t reach, the cost is still, sometimes, their life.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.